The management of cancer patients in clinical practice relies to a great extent on the results of clinical trials. Although several statistical methods are currently used to test the effects of treatments in clinical trials, all of them suffer from limitations. Moreover, it is not standard practice to take into account multiple endpoints to formally assess treatment results under a single metric. Very often, a new treatment yields positive results for the primary endpoint, but not for all secondary endpoints. Not incorporating the results of these other endpoints may lead to an incomplete view of the benefit/risk ratio.
Despite the promise of precision medicine, treatment choices could be taken one step further if patient preferences were taken into account in decision-making using a formal statistical framework. This might be called a truly “personalized medicine”. The speakers in this webinar have proposed a new statistical framework, named “generalized pairwise comparisons” (GPC), which can be useful in the search for personalized treatment choices.
In this webinar, expert speakers will:
- Review commonly used metrics to assess treatment benefit, especially considering survival endpoints
- Describe the GPC method as a novel approach to the analysis of clinical-trial data, providing examples of recent studies in which this method has been used and has shed new light on the assessment of treatment benefit
- Describe ongoing efforts to enhance this methodology and make it available to end-users, such as clinical trialists, physicians, and patients
Marc Buyse, ScD, Chief Scientific Officer, International Drug Development Institute (IDDI)
Marc Buyse holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA). He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe. He is interested in clinical trial design, meta-analysis, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and fraud, statistical monitoring of clinical trials, and medical data sharing (http://publicationslist.org/marc.buyse).
Everardo Saad, MD, Medical Director, International Drug Development Institute (IDDI)
Everardo Saad has over 15 years of experience in Medical Oncology and clinical trial designs. He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston. After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.
Who Should Attend?
Clinical trialists, statisticians, medical oncologists, physicians, patient advocates, and other professionals involved in the design, conduct and analysis of oncology trials and in the application of trial results into practice.
International Drug Development Institute (IDDI) is an expert center in biostatistical and integrated eClinical services for pharmaceutical and biotechnology companies in several disease areas, including oncology and ophthalmology.
IDDI optimizes the clinical development of drugs, biologics and devices thanks to proven statistical expertise and operational excellence. Founded in 1991, IDDI has offices in Belgium, Boston (MA), Raleigh (NC) and San Francisco (CA).